Emese Zsiros, MD, PhD, FACOG, discusses managing paclitaxel toxicity and the role of pembrolizumab maintenance in treating ...
Practical examples of advanced practice provider–led initiatives that improve safety, symptom management, and patient ...
Leopold, MD, explains how evidence-based integrative therapies like acupuncture and nutrition improve oncology patient ...
The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...
Rinatabart sesutecan (Rina-S) demonstrated a 100% disease control rate at the 100-mg/m 2 dose for patients with heavily ...
Jakel shared the story of a young mother who had been deemed difficult and “in denial” by other staff due to her rejecting ...
Optune Pax plus gemcitabine/nab-paclitaxel improved OS in ITT LA-PAC patients (16.2 vs 14.2 months; HR 0.82; P=.039) with higher 1-year survival. Modified per ...
The advantage of MCED testing is its potential to identify cancers at earlier, more treatable stages; detecting cancer even ...
RMAT status for KB707 enables expedited development with enhanced FDA engagement, supported by early KYANITE-1 activity and durability in heavily pretreated advanced/metastatic NSCLC. LungTIME-C01 ...
The FDA has accepted and granted priority review to a supplemental biologics license for datopotamab deruxtecan-dlnk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results